The prescription drug Horizant (gabapentin enacarbil) is currently protected by patents that prevent any generic versions from being made in the United States. The earliest predictable date that a generic version could become available is in 2022, when Horizant's patents expire.
Horizant™ (gabapentin enacarbil) is a prescription medication used to treat restless legs syndrome (RLS) and postherpetic neuralgia. It is an extended-release version of gabapentin.
Horizant is made by Patheon, Inc., for GlaxoSmithKline. The drug is protected against generic competition by patents, and no generic versions are available in the United States.
The patents for Horizant are currently set to expire in November 2022. This is the earliest predictable date that a generic version could become available. However, other circumstances could come up to extend or shorten the exclusivity period. This could include such things as other patents for specific Horizant uses or lawsuits.
No -- gabapentin is the active ingredient in Horizant (as well as in Neurontin®, Gralise™, and generic versions of Neurontin), but is not a generic version of it.
What can be confusing is that the active ingredient of any drug is often referred to as the "generic name." The generic name is different from a generic version of a medicine. In order for there to be a generic version of a medicine, the original medicine must have gone off-patent and another company besides the original manufacturer must make the product.